ArticleOncogene2002
Inactivation of Ras function by allele-specific peptide aptamers.
Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Nucleic Acid Therapeutics for "Undruggable" Cancer Targets: Mechanisms, Challenges, and Prospects.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Targeting the 'Undruggable' Driver Protein, KRAS, in Epithelial Cancers: Current Perspective.Cells · 2023Review
- Monobodies as tool biologics for accelerating target validation and druggable site discovery.RSC medicinal chemistry · 2021Review
- Targeting Ras with Macromolecules.Cold Spring Harbor perspectives in medicine · 2018Review
- Aptamers and their potential to selectively target aspects of EGF, Wnt/β-catenin and TGFβ-smad family signaling.International journal of molecular sciences · 2013Review
- The eleven-year switch of peptide aptamers.Journal of biology · 2008Review
- Bifunctional recombinant proteins in cancer therapy: cell penetrating peptide aptamers as inhibitors of growth factor signaling.Journal of cancer research and clinical oncology · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
One challenge facing biology is the elucidation of the function of the estimated 30 000 human genes and their polymorphic variants. Reagents that affect the activity of specific genes will be useful in the dissection of cellular regulatory networks. Here, as a test case, we used a two-bait two-hybrid system to identify peptide aptamers that distinguish allelic forms of H-Ras. Some of these anti-Ras aptamters inhibit the interaction of oncogenic Ras with c-Raf1 in vitro, and abolish EGF-stimulated activation of c-Raf1 in vivo. These experiments show that the inactivation of protein function by peptide aptamers represents a viable approach to the understanding and control of signaling pathways and oncogenic missense alleles.
Indexed as
Identifiers
12173045What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.